Finanzen von aTyr Pharma Inc (ATYR)ATYRaTyr Pharma Inc

Evaluating the bottom line, aTyr Pharma Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -98.37%, provide a clear picture of how effectively ATYR converts its operational activities into shareholder value.

In the context of the broader market, ATYR competes directly with industry leaders such as SCYX and CLNN. With a market capitalization of $54.40M, it holds a significant position in the sector. When comparing efficiency, ATYR's gross margin of N/A stands against SCYX's 100.00% and CLNN's 60.00%. Such benchmarking helps identify whether aTyr Pharma Inc is trading at a premium or discount relative to its financial performance.

aTyr Pharma has reported a narrowing net loss of $10.31 million in Q2 2026, down from $19.53 million in the same quarter last year, indicating improvements in operational efficiency. The company has a current ratio of 5.12, suggesting strong liquidity to cover short-term liabilities.